The use of sunitinib in renal cell carcinoma: where are we now?

被引：9

作者：

Czarnecka, Anna M. ^{[1
]}

Szczylik, Cezary ^{[1
]}

Rini, Brian ^{[2
]}

机构：

[1] Mil Inst Med, Mol Oncol Lab, Dept Oncol, Warsaw, Poland

[2] Cleveland Clin, Dept Solid Tumor Oncol, Taussig Canc Inst, Cleveland, OH 44106 USA

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2014年 / 14卷 / 09期

关键词：

biomarker; clear cell cancer; renal cell cancer; SU11248; sunitinib; tyrosine kinase; VEGF; TYROSINE KINASE INHIBITOR; ENDOTHELIAL GROWTH-FACTOR; CLINICAL-PRACTICE GUIDELINES; ADVERSE EVENT MANAGEMENT; PREDICTIVE FACTORS; INTERFERON-ALPHA; PHASE-II; TARGETED THERAPIES; 1ST-LINE TREATMENT; ANTITUMOR-ACTIVITY;

D O I：

10.1586/14737140.2014.941815

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Sunitinib malate (Sutent (TM)) is an inhibitor of multiple protein tyrosine kinases that shows antitumor and antiangiogenic activities. In a randomized Phase III trial of treatment-naive patients with metastatic renal cell carcinoma (mRCC), patients treated with sunitinib showed a significant improvement in progression-free survival compared with those treated with IFN-alpha. Sunitinib also exhibited antitumor activity in unselected RCC patients, including those with who were refractory to treatment, had non-clear cell histology brain metastases, or an Eastern Cooperative Oncology Group performance status > 1. Typical side effects of sunitinib malate are fatigue, asthenia, diarrhea, skin rash, stomatitis, hand-foot skin syndrome, hypothyroidism and hematological abnormalities. Hypertension, other toxicities may serve as biomarkers for improved clinical outcomes in sunitinib treatment. Currently, sunitinib remains the gold standard of care in the treatment of mRCC.

引用

页码：983 / 999

页数：17

共 50 条

[21] Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma
Holger Gerullis
Lothar Bergmann
Luise Maute
Thorsten Holger Ecke
Christoph Eimer
Jens Willem Bagner
Thomas Otto
Medical Oncology, 2010, 27 : 373 - 378
[22] Human Papillomavirus Testing in Head and Neck Squamous Cell Carcinoma in 2020: Where Are We Now and Where Are We Going?
James S. Lewis
Head and Neck Pathology, 2020, 14 : 321 - 329
[23] Perioperative use and surgical complications of Sunitinib in metastatic renal cell carcinoma
Thibault, F.
Billemonst, B.
Rixe, O.
EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 306 - 306
[24] Skin Cancer Associated With the Use of Sorafenib and Sunitinib for Renal Cell Carcinoma
Breaker, Kathryn
Naam, Mary
La Rosa, Francisco G.
Flaig, Insley P.
Flaig, Thomas W.
DERMATOLOGIC SURGERY, 2013, 39 (07) : 981 - 987
[25] Public use of AEDs in Europe: Where are we now and where are we going?
Chamberlain, D
Bossaert, L
Davies, S
Colquhoun, M
CARDIAC ARRHYTHMIAS 2003, 2004, : 555 - 561
[26] Perioperative use and surgical complications of Sunitinib in metastatic renal cell carcinoma
Thibault, Frederic
Billemont, Bertrand
Richard, Francois
Rixe, Olivier
JOURNAL OF UROLOGY, 2008, 179 (04): : 169 - 169
[27] Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma
Gerullis, Holger
Bergmann, Lothar
Maute, Luise
Ecke, Thorsten Holger
Eimer, Christoph
Bagner, Jens Willem
Otto, Thomas
MEDICAL ONCOLOGY, 2010, 27 (02) : 373 - 378
[28] Human Papillomavirus Testing in Head and Neck Squamous Cell Carcinoma in 2020: Where Are We Now and Where Are We Going?
Lewis, James S., Jr.
HEAD & NECK PATHOLOGY, 2020, 14 (02): : 321 - 329
[29] The clinical use of PET - where are we now?
Cook, GJR
BRITISH JOURNAL OF RADIOLOGY, 2001, 74 (881): : 399 - 401
[30] Axitinib in renal cell carcinoma: now what do we do?
Davis, Ian D.
TRANSLATIONAL CANCER RESEARCH, 2014, 3 (06) : 562 - 566

← 1 2 3 4 5 →